Predictive value of hematological and phenotypical parameters on postchemotherapy leukocyte recovery

Cytometry Part B - Clinical Cytometry

Volumn 76, Issue 5, 2009, Pages 328-333

  Bononi, A ^a   Lanza, F ^b   Ferrari, L ^b   Gusella, M ^a   Gilli, G ^c   Abbasciano, V ^b   Campioni, D ^b   Russo, A ^b   Menon, D ^a   Albertini, F ^a   Stievano, L ^a,b,c,d   Barile, C ^a   Crepaldi, G ^a   Toso, S ^a   Ferrazzi, E ^a   Pasini, F ^a  

^a Laboratory of Pharmacology and Molecular Biology   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

G CSF; LUCs; MPXI; Neutropenia

Indexed keywords

BIOLOGICAL MARKER; CD45 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE; MYELOPEROXIDASE; PACLITAXEL; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BLADDER CANCER; BLAST CELL; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CD34 SELECTION; CLINICAL ARTICLE; CYTOCHEMISTRY; FEMALE; FLOW CYTOMETRY; HEMATOLOGICAL PARAMETERS; HUMAN; LEUKOCYTE COUNT; LUNG NON SMALL CELL CANCER; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL CIRCULATION; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; STOMACH CANCER; TESTIS CANCER; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; CELL SEPARATION; FEMALE; FILGRASTIM; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; LEUKOCYTES; MALE; MIDDLE AGED; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 74849134653     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20476     Document Type: Article

References (23)

1. Drewinko B, Bollinger P, Brailas C, Moyle S, Wyatt J, Simson E, Johnston D, Trujillo JM. Flow cytochemical patterns of white blood cells in human haematopoietic malignancies. I. Acute leukaemias. Br J Haematol 1987;66:27-36.
2. Winkel P, Olesen T, Nissen NI. Automated cytochemistry in the prediction of remission following chemotherapy of patients with de novo acute myeloblastic leukemia. Am J Clin Pathol 1982;77:50-53.
3. Avnstrom S, Ralfkiar E, Winkel P, Nissen NI. The relative merit of various cytochemical quantities and manual differential count in predicting remission following chemotherapy of patients with de novo acute myeloblastic leukemia. Am J Clin Pathol 1985;83:73-76.
4. Drewinko B, Bollinger P, Brailas C, Wyatt J, Simson E, Trujillo JM. Flow cytochemical patterns of white blood cells in human haematopoietic malignancies. III. Miscellaneous hemopoietic diseases. Blood cells 1988;13:475-486.
5. Lanza F, Moretti S, Letorraca A, Scapoli GL, Rigolin F, Castoldi GL. Flow cytochemical analysis of peripheral lymphocytes in chronic Blymphocytic leukemia. Prognostic role of the blast count determined by the H*1 system and its correlation with morphologic features. Leuk Res 1992;16:639-646.
6. Bentley SA, Pergram MD, Ross DW. Diagnosis of infective and inflammatory disorders by flow cytometric analysis of blood neutrophils. Am J Clin Pathol 1987;88:177-181.
7. Bononi A, Lanza F, Dabusti M, Gusella M, Gilli. G, Menon D, Toso S, Crepaldi G, Scapoli D, Marenda B, Nocera F, Giuliano G, Ferrazzi E. Increased myeloperoxidase index and large unstained cell values can predict the neutropenia phase of cancer patients treated with standard dose chemotherapy. Cytometry 2001;46:92-97.
8. Leckie MJ, Bryan SA, Khan J, Dewar A, Aikman LS, McGrath J, Okrongly DA, Burman JF, Barnes PJ, Hansel TT. Automated quantitation of circulating neutrophils and eosinophil activation in asthmatic patients. Thorax 2000;55:471-477.
9. Bertino JR, Kamen B, Romanini A, Pizzorno G, Chemg YC, Handschumaker RE, Colvin OM, Myers C, Wozniak AJ, Ross W, Silber R, Beck WT, Cass CE, Houghton PJ. Chemotherapeutic agents. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, editors. Cancer Medicine, 4th ed. Baltimore, MD: Williams & Wilkins; 1997. pp 907-1045.
10. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Figrastim (r-metHuG-CSF): The first 10 years. Blood 1996;88:1907-1929.
11. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol 2007;25:3158-3167.
12. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. 2006 update of recommendations for the use of with blood cell growth factors: An evidence based clinical practice guideline. J Clin Oncol 2006;24:3187-3205.
13. Papaldo P, Lopez M, Marzolla P, Cortesi E, Antimi M, Terzoli E, Vici P, Barone P, Ferretti G, Di Cosimo S, Carlini P, Nisticò C, Conti F, Di Lauro L, Botti C, Di Filippo F, Fabi A, Giannarelli D, Calabresi F. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 2005;23:6908-6918.
14. Zipfel M, Carmine TC, Gerber C, Niethammer D, Bruchelt G. Evidence for the activation of myeloperoxidase by f-Meth-Leu-Phe prior to its release from neutrophile granulocytes. Biochem Biophys Res Commun 1997;232:209-212.
15. Bizzaro N, Briani G, Boccato P. Acquired myeloperoxidase defi-ciency of neutrophils in a patient with aplastic anemia (idiopathic marrow aplasia). Acta Haematol 1988;80:71-73.
16. + cells. J Biol Regul Homeost Agents 2003;18:5-15.
17. Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: A review of the evidence. J Natl Compr Canc Netw 2005;3:557-571.
18. Gombart AF, Kwok SH, Anderson KL, Yamaguchi Y, Torbett BE, Koeffler HP. Regulation of neutrophil and eosinophil secondary granule gene expression by transcription factors C/EBP and PU.1. Blood 2003;101:3265-3273.
19. Di Lauro L, Belli F, Arena MG, Carpano S, Paoletti G, Giannarelli D, Lopez M. Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer. Ann Oncol 2005;16:1498-1502.
20. Ottosson S, Magnusson K, Hultborn R. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery. Anticancer Res 1999;19:4429-4434.
21. Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J. A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 2001;91:1543-1548.
22. Jacobson JO, Grossbard M, Shulman LN, Neuberg D. CHOP chemotherapy with preventive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: A dose-intensity analysis. Clin Lymphoma 2000;1:211-217.
23. Greenfield HM, Sweeney DA, Newton RK, Leather A, Murray J, Angelica R, Swindell R, Chang J. Estimation of haemopoietic progenitor cells in peripheral blood by the Advia 120 and BD vantage flow cytometer: A direct comparison for the prediction of adequate collections. Clin Lab Haematol 2005;27:287-291.